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from the Circulation 
BY RICK L.  MEEK, JEFFREY S. HOFFMAN,  AND  EARL P. BENDITT 
From the Department of Pathology, University of Washington, Seattle, Washington 98195 
Serum  amyioid  A  (SAA) 1 is  presumed  to  be  the  precursor  for  amyloid  A 
protein,  the  main  protein  constituent  found  in  the  amyioid fibrils of reactive 
amyloidosis  (1-3).  In  the  mouse  SAA  is  encoded  by a  family  of three  genes 
(Morrow, John F., personal communication). SAA1 and SAA2 are synthesized in 
the liver by hepatocytes (4-10) and are found circulating in nearly equal quan- 
tities associated with high  density lipoprotein  (HDL) (11).  SAA3 mRNA is also 
expressed  in  the  liver;  however,  the  corresponding  polypeptide  has  not  been 
identified.  We have found that of the three possible SAA gene products, SAA2 
appears to be the sole precursor of murine amyloid fibril protein AA (12).  We 
wish to determine  by what mechanism  this  monotypic fibril formation  occurs. 
One can conceive of three ways in which this could come about: (a) the gene for 
SAA2 could be active in tissues in which the deposits occur; (b) amyloid A fibril 
protein could be derived from a circulating SAA2 precursor whose concentration 
is selectively enhanced relative to the other SAA proteins during the induction 
of the  disease process;  and  (c) there  could be selective SAA~ removal  from  a 
circulating  pool  of possible precursors  and  deposition  of SAA2 as  amyloid  A 
protein. 
We designed  the  experiments  described  here  to  decide among  these  three 
alternatives.  To differentiate among the several possible mechanisms of amyloi- 
dosis,  we  searched  for  evidence  of local  SAA  synthesis  and  examined  SAA 
metabolism  during  amyloid  induction  at  the  level  of SAA  gene  expression, 
synthesis, secretion, and circulatory levels. We conclude that anayloid A protein 
monotypy is not due to local SAA2 production,  nor is it a reflection of selective 
increase of SAA2 isotype levels in the circulation.  However, it does involve the 
selective and rapid removal of SAA2 from the circulating pool of both SAA~ and 
SAAz.  Our  experimental  analysis clearly indicates  that  a  combination  of some 
feature of SAA~ interacting with itself and/or local tissue constituents is respon- 
sible for  the appearance  of amyloid  fibrils  with  AA2 as the  major  constituent 
peptide. 
Materials and Methods 
Amyloid Induction  and Histological Evaluation  of Tissue Amyloid Deposits.  Male CBA 
mice  2-3  mo old were used throughout the study.  Amyloidosis was induced by daily 
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subcutaneous injection of casein as described by Benson (13).  At 0, 1, 5, 10,  15, and 20 d 
during casein-injection, animals were anesthetized, bled, and the spleens and livers were 
removed.  5-um histological sections of spleens were examined by polarized light after 
staining with Congo red (14). The areas of specific Congo red dichroic birefringence were 
found to correlate well with the area of the hyaline material observed in adjacent tissue 
sections stained with hematoxylin and eosin (data not shown); hence, for ease of measure- 
ments, tissues stained with the latter were used for morphometry (15) to estimate splenic 
amyloid content.  At  each  time point  four  randomly  chosen  fields  from each  of four 
spleens were quantitated. Relative areas were estimated with a 400-point grid on projected 
sections enlarged -400 times, and amyloid content was computed as the percent of spleen 
occupied by the amyloid deposits. 
RNA Isolation and Cell-free Translation.  Liver RNA was isolated after homogenization 
of tissue in SDS-proteinase K buffer (16).  RNA was obtained from spleens after homoge- 
nization in guanidium isothiocyanate (17). 
Cell-free translation of total RNA (200 #g/ml) or poly A + RNA (50 #g/ml) was carried 
out in a rabbit reticulocyte translation system (18) in the presence of L-[~SS]methionine 
(New England Nuclear, Boston, MA; 1 mCi/ml, >1,000 Ci/mM). SAA translation products 
(preproteins) were immunoprecipitated with rabbit anti-apoSAA antibody, affinity-puri- 
fied as previously described  (6).  Immune complexes were  recovered by absorption to 
pansorbin (Calbiochem-Behring, La Jolla, CA). The washed precipitates were solubilized 
by boiling for 2  rain  in  SDS sample buffer (19)  and analyzed by SDS-urea-PAGE and 
fluorography.  The  microsome preparation  used  in  the  cell-free translations  was a  gift 
from Dr. Mark Lively (20). 
Hepatocyte Isolation  and Culture.  Hepatocytes were harvested as described previously 
(6) from mice 1 or 20 d after initiation of casein treatment. Routine yields were 20-40 x 
106 hepatocytes per liver with ~90% viability as judged by trypan blue exclusion. Washed 
hepatocytes were resuspended in media containing 10% FCS and 3 X 106 cells were placed 
into 25 cmz flasks (Corning Glassworks, Corning, NY). After 6 h, the medium was replaced 
with RPMI 1640 without FCS or methionine. After a 30-rain incubation this medium was 
replaced with the same medium containing L-[35S]methionine  (200 #Ci/ml) and aprotinin 
(100 #g/ml; Sigma Chemical Co., St. Louis, MO) for 4 h. The medium was then removed 
and an aliquot of each medium was prepared for SDS-urea-PAGE. 
Radioimmunoassay,  IEF, and SDS-Urea-PAGE and Densitometry.  Blood was collected by 
cardiac puncture of ether-anesthetized mice. Serum SAA concentrations were determined 
by RIA as previously described (11).  HDL was then prepared from serum of individual 
mice by sequential ultracentrifugation and the delipidated apoproteins were analyzed by 
equilibrium IEF in pH 3.5-10.0 ampholine gradients (LKB Instruments, Inc., Gaithers- 
burg, MD) (11).  SDS-urea polyacrylamide gels were prepared and used as described (6). 
After electrophoresis slab gels were fixed and prepared for fluorography with EN3HANCE 
(New  England  Nuclear)  and  exposed to  X-omat AR  film  (Eastman  Kodak  Company, 
Rochester, NY).  Fluorographs and stained IEF gels were quantified using a microdensi- 
tometer (Joyce Loebl and Co., Malden, MA) equipped with an integrator. 
Recombinant  SAA  cDNA.  A  recombinant  SAA  cDNA  clone  was  isolated  using  the 
procedures described by Maniatis et al. (21).  Briefly, poly A ÷ RNA was isolated from the 
liver of a male Balb/c mouse 20 h after an intraperitoneal injection of LPS (11).  Double 
stranded cDNA was synthesized and inserted into the plasmid pBR322 by the G-C tailing 
method. The chimeric plasmids were used to transform E.  coli strain RRI. After differ- 
ential colony screening (22) of tetracycline resistant clones with ~zP-labeled cDNA derived 
from poly A ÷ liver RNA of normal and LPS-stimulated Balb/c mice, potential SAA cDNA 
clones  were  rescreened  by hybrid  selection  of SAA  mRNA.  SAA  cDNA  clones were 
identified by cell-free translation of hybrid selected mRNA (21) and identification of SAA 
translation products on SDS-urea polyacrylamide gels.  One clone (pSAA1) with an SAA 
cDNA insert of-400 bp, hybrid-selected SAA~ and SAA~ mRNA equally (data not shown) 
and was confirmed to code for SAA~ (23) by its nucleotide sequence (24).  The 5' end of 
this clone (unpublished results) covers the highly conserved region spanning amino acid 
residues 32 to 44 found in the three SAAs and the amyloid A protein (25). MEEK  ET  AL.  501 
Northern  Blot Analysis.  RNA  was  denatured  and  electrophoresed as  described by 
Lehrach et al. (26). Total RNA (0.5 mg/ml) was denatured at 60°C for 15 min. 5 #g of 
RNA was then electrophoresed through  1.5%  agarose gels buffered with  10 mM phos- 
phate, 5 mM NaOAc, 1 mM EDTA, and containing 3% formaldehyde. Fractionated RNA 
was transferred to nitrocellulose in 20X SSC (3 M NaCI, 0.3 M sodium citrate, pH 7.0) 
and baked at 80°C. Hybridization was carried out using buffers essentially described by 
Wahl et al. (27). Prehybridization buffer contained 50% formamide, 5x SSC, 4x Denharts, 
150 •g/ml  herring sperm DNA,  100 mM NaH~PO4,  1% glycine, and 50 t~g]ml polyade- 
nylic acid (poly A). Prehybridization was for 2 h at 45 °C. Hybridization buffer contained 
four parts prehybridization buffer and one part 50% (wt/vol) dextran sulfate. Hybridiza- 
tion was performed at 45°C  for  16-18 h  with  106 cpm/ml denatured,  nick-translated 
(28), SAA-specific cDNA (10  s cpm/#g) isolated from pSAA~.  RNA blots were washed 
three times at room temperature with 2x SSC, 0.1% SDS for 20 min each, followed by 
three washes  in 0.1x SSC, 0.1% SDS at 55°C for 15 rain each. Comparison of SAA~.2.3 
mRNA sequences (John F. Morrow, personal communication; 23) revealed that SAA~ and 
SAA2  are  highly conserved with 96%  homology. SAA3 mRNA is  73% homologous to 
SAA~ mRNA,  but contains a  150-nucleotide region of 90%  homology to our pSAA~ 
cDNA. Using these standard blot washing conditions, regions of ~90% homology would 
form  stable  hybrids.  28S  and  18S  RNA  were  visualized  on  the  nitrocellulose after 
autoradiography of the blot by staining in 0.04% methylene blue in 0.5 M sodium acetate, 
pH 5.5. 
Results 
Time  Course  of Amyloid  Deposition.  The  changes  with  time  of the  relative 
volume of splenic tissue occupied by amyioid substance is shown in Fig.  1. With 
either Congo red or H  & E staining, no amytoid material was detected until day 
5, at which time ~2%  of splenic volume was occupied. The quantity of amyloid 
substance increased rapidly thereafter, and by day 20 represented ~30% of the 
total spleen volume. 
There  is No Detectable  Synthesis  of SAA by the Spleen.  In  order to determine 
whether  or not  spleen  cells contribute  to amyloid  substance  accumulation  via 
SAA synthesis and secretion, a recombinant SAA cDNA, which hybridizes to,all 
three SAA sequences, was used to detect SAA mRNA. Fig. 2 shows the result of 
hybridizing the  ~P-labeled  SAA  cDNA  to liver RNA,  which synthesizes large 
amounts  of SAA  in  response  to  inflammatory  stimuli,  and  spleen  RNA  after 
electrophoresis through agarose and transfer to nitrocellulose. Liver SAA mRNA 
was elevated to a  high level  1 d  after casein injection (lanes  1 and 2).  No SAA 
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FIGURE  I.  Time course of amyloid deposition. At the indicated times spleens were removed 
and prepared for histological examination. As described in Materials and Methods, amyloid 
cross-sectional area was computed by morphometry. Time points represent mean percentages 
from four fields of each of four spleens. 502  REMOVAL OF SERUM AMYLOID A2 FROM THE CIRCULATION 
FIGURE 2.  Northern gel analysis of liver and spleen RNA. Total RNA from liver and spleen 
was isolated at various times during amyloid induction. 5 #g of RNA were then separated on 
agarose (1.5%) formaldehyde denaturing gels, transferred to nitrocellulose, and the nitrocel- 
lulose  filter  was  hybridized  to  nick  translated  SAA  cDNA  as  described  in  Materials  and 
Methods. The RNA examined was extracted from the following tissues: Lane 1 and 2 are liver 
from either uninjected animals (lane 1) or 1 day after casein injection (lane 2). Lanes 3-6 were 
from spleens from uninjected animals (lane 3) or from animals after 7,  14 and 21  d of casein 
injections, respectively. The position of the 28s and 18s ribosomal RNA is indicated. 
mRNA was detected in spleen of control animals  or during amyloid substance 
deposition (lanes 3-6). Quantitative Northern blot analysis at a sensitivity capable 
of detecting ~> 1% of normal liver SAA mRNA did not reveal splenic SAA mR NA 
(data not shown). In addition, no SAA products could be detected from the cell- 
free translation  of splenic RNA (data not shown). Furthermore,  no SAA mRNA 
was detected after casein injection in a variety of other tissues examined (unpub- 
lished observation). 
Circulating Levels of  SAAs.  Serum SAA levels 1 d after the first casein injection 
(Fig.  3),  were elevated >50-fold above baseline (280  ___ 58 #g/ml).  Thereafter, 
SAA levels remained elevated but slowly declined to a low of ~110 +  35 #g/ml 
by day 15 and remained at this level despite continued casein injections. 
Analysis of SAA~ and SAA2 levels revealed that on day 1 SAAI was 120 ~g/ml 
while SAA2 was  160 #g/ml (SAA2/SAA1 ratio,  1.98).  Over the next  19 d  SAAI 
dropped slightly to  100 #g/ml while the SAA2 level dropped dramatically to  15 
#g/ml  (SAAz/SAA~ ratio,  0.15).  A  second similar experiment  (data not shown) 
yielded essentially the same result, although  total serum  SAA rose to only  190 
gg/ml, the SAA~/SAA~ ratio declined with similar kinetics from  1.4 on day 1 to 
0.12 on day 20. 
Changes in Hepatic SAA~ and SAA2 mRNA Assayed by Celt-free Translation.  In 
order to  measure  hepatic  SAA~  and  SAA2 mRNA  levels,  we first determined MEEK  ET  AL.  503 
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FIGURE  3.  Serum SAA levels during amyloid induction (amyloidogenesis). Serum was col- 
lected from  mice as described under Materials and Methods and SAA concentration deter- 
mined by RIA.  The concentration of circulating SAA1  and SAA~ during amyloid induction 
was determined as follows: animals were bled and HDL isolated as described under Materials 
and Methods. The HDL apoproteins from four animals at each time point were separated on 
equilibrium IEF gels, and SAA2 to SAA~  ratios quantitated to be  1.28 +  0.13,  0.75 __. 0.25, 
0.95 ±  0.12, 0.35 +  0.14, 0.15 _  0.01 for day 1 through day 20 consecutively. The ratio data 
was then used  to estimate the concentration of SAA~  and SAA~ from the total SAA levels 
determined by RIA. The number at the top of each bar is the SAA2/SAAt ratio. 
FIGURE 4.  Identification of SAAt  and SAA~ cell-free translation products.  Poly  A + RNA 
isolated from murine liver 24 h after casein was translated in the presence of [sSS]methionine, 
antibody precipitated, and separated on an SDS-urea-polyacrylamide gels as described under 
Materials and Methods. (a)  In lane  I  antibody precipitation with hyperimmune rabbit IgG; 
lane 2, antibody precipitation with affinity-purified anti-SAA antibody; and lane 3, as in lane 
2,  but  in the presence of murine protein AA (100 #g/ml).  (b) Cell-free translation of total 
RNA isolated from mouse liver 24 h after casein injection and antibody precipitated as in Fig. 
4a,  lane  1,  translation  without  microsomes;  and  lane  2,  translation  in  the  presence  of 
microsomes.  The  position  of SAAI  and  SAA~  HDL  apoproteins  is  indicated  in  the  right 
margin. 
that  SAA1  and  SAA2 preproteins  synthesized  in  a  cell-free translation  system 
could be identified.  Poly A + RNA isolated from murine  liver 20 h  after casein 
injection was translated  in the presence of L-[sSS]methionine.  Two polypeptides 504  REMOVAL OF SERUM AMYLOID A2 FROM THE CIRCULATION 
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FIGURE 5.  (top) Time course  of SAAI and  SAA~ mRNA  level during amyloid induction. 
s5  Total RNA was isolated from murine  liver, translated  in the presence of L-[  S]methionine, 
and antibody precipitated as described. Total ssS counts per minute was determined by TCA 
precipitation. The antibody precipitate from 200,000 cpm of total TCA precipitated translated 
proteins  was  separated  on  SDS-urea-polyacrylamide  gels.  A  representative  fluorograph  is 
shown in this figure. (bottom) Ratio of SAA1 and SAA~ mRNA during amyloid induction.  L- 
[35S]methionine, SAA antibody-precipitated translation products were separated on SDS-urea- 
polyacrylamide gels and radiofluorographs prepared (as in top). SAAI and SAA~ preproteins 
were quantitated by microdensitometry of appropriately exposed fluorographs. The number 
at the top of the bars is the SAA2/SAA~ preprotein ratio. RNA from two livers at each time 
point was analyzed. 
were specifically immunoprecipitated in approximately equal amounts (Fig. 4a, 
lanes  1  and  2),  and  as  expected  of preproteins,  migrated  with  mobilities  of 
peptides appropriately larger than SAA~ and SAA2. Pretreatment of the antibody 
with murine protein AA completely blocked antibody precipitation of the trans- 
lated  proteins (lane  3).  Fig.  4b  depicts results  of cell-free  translations  of total 
RNA in the absence (lane 1) or presence (lane 2) of microsomes (which remove 
the NH2 terminal signal peptide from secretory proteins) (29). As in Fig. 4a, two 
SAA preproteins are immunoprecipitated from the reaction. Translations carried MEEK  ET  AL.  505 
FIGURE 6.  Secretion  of  SAA  by  hepatocytes.  Hepatocytes  were  isolated  and  labeled  as 
described under Materials and Methods from mice (a) 1 d or (b) 20 d after the start of casein 
injections. Equal volumes of media from a 25-cm  2 flask containing 3 X 106 cells were analyzed 
from each sample. Identification of SAA~ and SAA2 HDL apoproteins is in the left margin. 
out in  the presence of microsomes result in processed SAA proteins with the 
same mobility as authentic SAAI and SAA2 isolated from HDL. 
The relative abundance of hepatic SAAI and SAA2 mRNA was determined 
by quantitation of [aSS]methionine-labeled SAA1 and SAA2 preproteins, identi- 
fied after cell-free translation  of liver mRNA obtained from animals over the 
time course of amyloid induction.  Fig.  5 (top)  shows the following: no specific 
radioactivity was precipitated in  translation products  from uninduced animals 
(lane  1).  One day after casein injection, SAA translation  products were easily 
detected and represented -3.4%  of total  TCA precipitable counts translated. 
The level of SAA translation products showed a gradual decline and by day 20 
was ~30%  of that at day 1.  As shown in Fig.  5(bottom),  the relative SAAI and 
SAA2 preprotein levels did not change significantly over the course of the amyloid 
deposition (day 1,  1.36;  day 20,  1.23). This result is in contrast to the ratios of 
circulating SAAz/SAAI shown in  Fig.  2,  and clearly shows that the SAA1 and 
SAA2 mRNA ratio is not altered during amyloidogenesis. 
Synthesis  and Secretion  of SAA by Hepatocytes  In Vitro.  Although hepatic SAA1 
and SAA2 mRNA ratios  remained unchanged during amyloid deposition,  the 
relative rates  of mRNA  translation  or relative efficiency of secretion may be 
changed and result in altered SAA2 to SAA~ ratio in the circulation. We obtained 
information on  the  relative  rates  of secretion of each SAA  isotype by  intact 
hepatocytes from freshly isolated hepatocytes 1 and 20 d after initiation of casein 
injections (Fig. 6). Proteins secreted into the medium during a 4-h labeling period 
with  [~SS]methionine were  separated  by SDS-urea-PAGE and  the  quantity of 
SAA1 and SAA2 estimated by microdensitometry of appropriately exposed au- 
toradiographs  (data  not  shown).  Although  the  amount  of each  SAA  isotype 
secreted by hepatocytes after 20 d  of casein injection was reduced to ~25%  of 
that secreted after day 1, the ratio of SAA2/SAA1 on day 1 and day 20 was the 506  REMOVAL OF SERUM AMYLO1D A~ FROM THE CIRCULATION 
same (1.27).  This result is in good agreement with the relative levels of SAA~ 
and SAAz mRNA (Fig.  4),  and taken together these data show that SAAL and 
SAAz mRNA levels and their synthesis and secretion by the liver decline in a 
parallel manner during induction of amyloidosis by multiple casein injections. 
Discussion 
Amyloidosis  of the  reactive  variety  may  complicate  chronic  inflammatory 
diseases such as rheumatoid arthritis and tuberculosis (2). Extracellular amyioid 
deposits composed of fibrils accumulate in extracellular locations in a variety of 
tissues, resulting in organ dysfunction (!-3, 12, 30-37). The fibrils are composed 
mainly of protein  AA, an  8.5-kD  peptide homologous with the NH2-terminal 
portion of the acute-phase HDL-associated apoprotein, serum amyloid A protein. 
What is the underlying cause of amyloid formation? The commonly accepted 
hypothesis of amyloid deposition is that amyloid fibril protein A is derived from 
circulating SAA because of its sustained high levels during chronic inflammatory 
conditions.  However,  no  certain  evidence has  been  produced  to  sustain  this 
supposition.  Although  an  elevated  SAA level  is  a  predisposing condition  for 
amyloid formation, high SAA levels alone are not sufficient. Of patients with 
chronic inflammatory diseases,  only some individuals develop amyloidosis (2). 
Mouse model systems do  not show a  1:1  correlation between SAA level and 
susceptibility to amyloid deposition (13, 38).  Therefore, it appears that factors 
other than high SAA levels are involved in the pathogenesis of amyloidosis. 
Our recent evidence that murine protein AA is derived from only one SAA 
isotype (12) indicates that an important feature of murine amyloidosis involves a 
mechanism specific for SAA2 deposition. SAA2 overproduction could result in 
ineffective degradation during normal catabolic mechanisms, or SAA1 synthesis 
could cease during the long inflammatory period of amyloid deposition, leaving 
only SAA2 as a possible circulating precursor to AA protein. Another possibility 
is that structural features of the SAA2 protein alone may confer amyloidogenic 
potential without the need for altered metabolic pathways, or that SAA2 could 
be synthesized and deposited locally rather than derived from the circulation as 
suggested by other investigators (39-45),  and as is  the case in  endocrine and 
cutaneous amyloidosis (46).  In order to differentiate among the several possible 
mechanisms of amyloidosis, we searched for evidence of local SAA synthesis and 
examined SAA metabolism during amyloid induction at the level of SAA gene 
expression, synthesis, and secretion and circulatory levels. 
Having used a probe capable of detecting all three expressed SAA genes (Fig. 
2),  our findings that at  no time during amyloid formation does splenic tissue 
contain detectable levels of SAA mRNA leave no doubt that the source of AA 
protein in the mouse is not local, but must be sequestered from the circulation. 
In addition, to determine if tissues other than liver synthesized SAA, we searched 
for SAA  mRNA  in  RNA  extracted from  lung,  heart,  kidney, brain,  skeletal 
muscle, and testis. We did not detect SAA mRNA in normal controls or at any 
time during amyloid induction in these tissues. 
Our analysis of circulating SAA showed that monotypic amyloid formation is 
not a reflection of  circulating SAA2 levels, either by having a large preponderance 
of SAA2 compared with SAAj or by the lack of circulating SAAj. In fact, SAA2 MEEK ET  AL.  507 
serum levels are substantially reduced during the course of amyloid formation. 
This  could  be  due  to  differential isotype  synthesis and  secretion  or  altered 
clearance from the circulation. However, the relative levels of SAA1 and SAA2 
mRNA  remained constant  (Fig.  5),  as  did  the  amounts  of SAAl  and  SAA2 
synthesized  and  secreted  by  hepatocytes  (Fig.  6).  The  tenable  explanation, 
therefore, is that SAA2 is removed from the circulation faster than SAA~. This 
differential clearance of SAA isotypes is in marked contrast to equal clearance 
rates of SAA1 and SAA2 observed in normal mice (47) and mice during an acute 
phase  response  (Hoffman, Jeffrey S.,  unpublished observation).  Thus protein 
AA monotypy in murine amyloid deposits must be the result of events that favor 
the rapid local removal of SAA2 from a circulating pool containing both SAA1 
and SAA2. 
Several factors may make SAA2 amyloidogenic. The structure of the SAA2 
polypeptide may be  important  for amyloid deposition.  Comparison  of mouse 
SAA~  and  SAA2  sequences  deduced  from  cloning  data  (Morrow,  John  F., 
personal  communication) (23)  reveals nine  relatively conservative amino acid 
residue differences. Among them is a third methionine residue at position 76 in 
SAA2. Our amino acid analysis data (34) indicate that this third methionine is 
included in  the murine protein AA polypeptide (the  NH2 terminal portion of 
SAA2, ~8.5 kD). It is of interest that in an autosomal dominant form of genetically 
determined amyloidosis, familial amyloidotic polyneuropathy (FAP), a  variant 
transthyretin is synthesized with a methionine substitution for a valine. Both the 
normal and variant proteins are found in the circulation, but only the variant 
transthyretin accumulates as amyloid fibrils (48,  49).  This suggests that in the 
local  environment  where  amyloid  deposits  occur,  an  additional  methionine 
residue may confer increased protein-cell and/or protein-protein affinities. How- 
ever, the significance of an additional methionine residue or other amino acid 
differences between SAAz and SAA~ awaits further investigation.  In addition, 
further studies are necessary to elaborate the details surrounding the nature of 
the  interaction of SAA2,  leading to  its  rapid  and  selective removal from the 
circulation and resulting in local amyloid deposition. 
Summary 
The deposits of fibrils found in amyloidosis of the A  type are derived from 
only one of the three serum amyloid A (SAA) gene products, namely SAA2.  In 
order to  explore the mechanism of SAA isotype-specific amyloid protein  AA 
deposition, the molecular kinetics of the serum amyloid proteins were examined 
in  CBA  mice  during  casein  induction  of amyloidosis.  The  presence of SAA 
mRNA in spleen was searched for; hepatic SAA1 and SAA2 mRNA levels, rates 
of specific protein synthesis and secretion by hepatocytes, and serum levels were 
measured during a 20-d period of amyloid induction. We observed the following: 
small amounts ofamyloid substance appeared in the spleen by day 5 and increased 
steadily over the ensuing 15 d  to occupy nearly 30%  of splenic volume by day 
20.  No  SAA mRNA was detected in  spleen at any time during induction of 
amyloid formation. Total serum SAA levels peaked  1 d  after we began casein 
treatment, and thereafter declined. This decline was accounted for entirely by a 
dramatic fall in SAA2, while SAA1 levels remained nearly constant throughout. 508  REMOVAL OF SERUM AMYLOID A2 FROM THE CIRCULATION 
The ratios of hepatic SAA2:SAA~  mRNA, as determined by in vitro translation, 
remained constant  during the 20-d period, as did amounts of SAA,  and SAA2 
synthesized and secreted by freshly isolated hepatocytes. These data indicate that 
the deposition of amyloid A protein derived from SAA2 is not due to local SAA 
production in spleen, nor excessive SAA2 production compared with SAA,, but 
involves the selective and accelerated removal of SAA2 from the circulating pool 
of both SAA~ and SAA2. 
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